Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

Compare

58 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIK Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Hikma

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIK Stock 12 Month Forecast

Average Price Target

2,464.17p

▲(26.95% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is 2,464.17p with a high forecast of 2,650.00p and a low forecast of 2,000.00p. The average price target represents a 26.95% change from the last price of 1,941.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1810":"1,810p","2651":"2,651p","2020.25":"2,020.3p","2230.5":"2,230.5p","2440.75":"2,440.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2650,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.65K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2464.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.46K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">2.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1810,2020.25,2230.5,2440.75,2651],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1999,2049.076923076923,2099.153846153846,2149.230769230769,2199.3076923076924,2249.3846153846152,2299.4615384615386,2349.5384615384614,2399.6153846153848,2449.6923076923076,2499.769230769231,2549.846153846154,2599.923076923077,{"y":2650,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1999,2034.7823076923078,2070.5646153846155,2106.3469230769233,2142.1292307692306,2177.9115384615384,2213.693846153846,2249.476153846154,2285.2584615384617,2321.0407692307695,2356.8230769230768,2392.6053846153845,2428.3876923076923,{"y":2464.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1999,1999.076923076923,1999.1538461538462,1999.2307692307693,1999.3076923076924,1999.3846153846155,1999.4615384615386,1999.5384615384614,1999.6153846153845,1999.6923076923076,1999.7692307692307,1999.8461538461538,1999.923076923077,{"y":2000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1877.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1873.06,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1811.92,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1843.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1938.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1877,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1839.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1899.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1957.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2251.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2121.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1948,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1999,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,650p

Average Price Target2,464p

Lowest Price Target2,000p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Victor Floc'h

Exane BNP Paribas

2,650p

Buy

36.53%

Upside

Initiated

05/14/25

Emily Field

Barclays

2,000p

Hold

3.04%

Upside

Reiterated

04/25/25

Christian Glennie

Stifel Nicolaus

2,650p

Buy

36.53%

Upside

Reiterated

04/24/25

James Vane

Jefferies

2,090p→2,400p

Buy

23.65%

Upside

Upgraded

04/10/25

Victoria Lambert

Berenberg Bank

2,560p

Buy

31.89%

Upside

Reiterated

03/11/25

James Gordon

J.P. Morgan

―

Buy

―

Reiterated

03/07/25

Alistair Campbell

RBC Capital

2,375p→2,525p

Buy

30.09%

Upside

Reiterated

02/27/25

Thibault Boutherin

Morgan Stanley

2,100p→2,400p

Hold

23.65%

Upside

Reiterated

02/12/25

Paul Cuddon

Deutsche Bank

2,750p→3,100p

Buy

59.71%

Upside

Reiterated

11/25/24

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Victor Floc'h

Exane BNP Paribas

2,650p

Buy

36.53%

Upside

Initiated

05/14/25

Emily Field

Barclays

2,000p

Hold

3.04%

Upside

Reiterated

04/25/25

Christian Glennie

Stifel Nicolaus

2,650p

Buy

36.53%

Upside

Reiterated

04/24/25

James Vane

Jefferies

2,090p→2,400p

Buy

23.65%

Upside

Upgraded

04/10/25

Victoria Lambert

Berenberg Bank

2,560p

Buy

31.89%

Upside

Reiterated

03/11/25

James Gordon

J.P. Morgan

―

Buy

―

Reiterated

03/07/25

Alistair Campbell

RBC Capital

2,375p→2,525p

Buy

30.09%

Upside

Reiterated

02/27/25

Thibault Boutherin

Morgan Stanley

2,100p→2,400p

Hold

23.65%

Upside

Reiterated

02/12/25

Paul Cuddon

Deutsche Bank

2,750p→3,100p

Buy

59.71%

Upside

Reiterated

11/25/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hikma Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy GB:HIK and Sell After:

1 Month

xxx

Success Rate

9/12 ratings generated profit

Average Return

+4.08%

upgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.08% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

+0.83%

upgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.83% per trade.

1 Year

James GordonJ.P. Morgan

Success Rate

9/17 ratings generated profit

Average Return

-0.49%

reiterated a buy rating 2 months ago

Copying James Gordon's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of -0.49% per trade.

2 Years

xxx

Success Rate

3/7 ratings generated profit

Average Return

-5.73%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -5.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIK Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HIK has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HIK average Analyst price target in the past 3 months is 2,464.17.

Each month's total comprises the sum of three months' worth of ratings.

HIK Financial Forecast

HIK Earnings Forecast

The previous quarter’s earnings for HIK were 0.47p.

HIK Sales Forecast

The previous quarter’s earnings for HIK were 1.21B.

HIK Stock Forecast FAQ

What is GB:HIK’s average 12-month price target, according to analysts?

Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,464.17.

What is GB:HIK’s upside potential, based on the analysts’ average price target?

Hikma Pharmaceuticals PLC has 26.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?

Hikma Pharmaceuticals PLC has a consensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Hikma Pharmaceuticals PLC’s share price target?

The average share price target for Hikma Pharmaceuticals PLC is 2,464.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,650.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 26.95% Increase from the current price of 1,941p.

What do analysts say about Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Hikma Pharmaceuticals PLC?

To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

HIK Analyst Ratings

HIK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hikma Pharmaceuticals

HIK Analyst Recommendation Trends

HIK Financial Forecast

HIK Earnings Forecast

HIK Sales Forecast

HIK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts